Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-10-22 4:32 pm Sale | 2025-10-20 | 13D | LAVA Therapeutics N.V. LVTX | Cooperatieve Gilde Healthcare IV U.A. | 1,014,751 3.900% | -1,933,030 (-65.58%) | Filing History |
| 2025-10-17 6:01 pm Sale | 2025-10-15 | 13D | LAVA Therapeutics N.V. LVTX | Cooperatieve Gilde Healthcare IV U.A. | 2,947,781 11.200% | -2,298,711 (-43.81%) | Filing History |
| 2025-10-14 4:37 pm Purchase | 2025-10-09 | 13D | LAVA Therapeutics N.V. LVTX | Cooperatieve Gilde Healthcare IV U.A. | 5,246,492 19.900% | 5,246,492 (New Position) | Filing History |
| 2025-09-26 4:01 pm Purchase | 2025-09-19 | 13G | LAVA Therapeutics N.V. LVTX | Shay Capital LLC | 2,596,403 9.900% | 2,596,403 (New Position) | Filing History |
| 2025-09-23 4:52 pm Sale | 2025-09-19 | 13D | LAVA Therapeutics N.V. LVTX | Versant Venture Capital VI L.P. | 0 0.000% | -2,370,533 (Position Closed) | Filing History |
| 2025-09-18 7:08 pm Sale | 2025-09-16 | 13D | LAVA Therapeutics N.V. LVTX | Versant Venture Capital VI L.P. | 2,370,533 9.000% | -1,036,624 (-30.42%) | Filing History |
| 2025-03-03 2:03 pm Purchase | 2025-02-26 | 13G | LAVA Therapeutics N.V. LVTX | BML Investment Partners, L.P. | 1,958,110 7.400% | 1,958,110 (New Position) | Filing History |
| 2024-03-07 7:09 pm Sale | 2024-03-05 | 13D | LAVA Therapeutics N.V. LVTX | Novo Holdings A/S | 0 0.000% | -1,878,194 (Position Closed) | Filing History |
| 2024-02-14 4:26 pm Sale | 2023-12-31 | 13G | LAVA Therapeutics N.V. LVTX | Redmile Group LLC | 2,074,372 7.900% | -741,824 (-26.34%) | Filing History |
| 2023-11-09 4:37 pm Sale | 2023-11-03 | 13D | LAVA Therapeutics N.V. LVTX | Novo Holdings A/S | 1,878,194 7.100% | -521,806 (-21.74%) | Filing History |
| 2023-06-05 8:18 pm Sale | 2023-06-05 | 13D | LAVA Therapeutics N.V. LVTX | Novo Holdings A/S | 2,400,000 9.130% | -670,558 (-21.84%) | Filing History |
| 2023-02-24 4:38 pm Sale | 2023-02-22 | 13D | LAVA Therapeutics N.V. LVTX | Novo Holdings A/S | 3,070,558 11.700% | -256,754 (-7.72%) | Filing History |
| 2022-10-03 4:15 pm Unchanged | 2022-09-27 | 13D | LAVA Therapeutics N.V. LVTX | Novo Holdings A/S | 3,327,312 12.900% | 0 (Unchanged) | Filing History |
| 2022-09-30 4:45 pm Unchanged | 2022-04-21 | 13D | LAVA Therapeutics N.V. LVTX | Novo Holdings A/S | 3,327,312 8.600% | 0 (Unchanged) | Filing History |
| 2022-02-14 5:07 pm Sale | 2021-12-31 | 13G | LAVA Therapeutics N.V. LVTX | Redmile Group LLC | 2,816,196 10.900% | -8,213 (-0.29%) | Filing History |
| 2021-04-08 4:31 pm Purchase | 2021-03-29 | 13D | LAVA Therapeutics N.V. LVTX | Versant Venture Capital VI L.P. | 3,407,157 13.400% | 3,407,157 (New Position) | Filing History |
| 2021-04-08 4:11 pm Purchase | 2021-03-29 | 13G | LAVA Therapeutics N.V. LVTX | Redmile Group LLC | 2,824,409 11.100% | 2,824,409 (New Position) | Filing History |
| 2021-03-31 4:33 pm Purchase | 2021-03-24 | 13D | LAVA Therapeutics N.V. LVTX | Novo Holdings A/S | 3,327,312 13.100% | 3,327,312 (New Position) | Filing History |
| 2021-03-31 11:19 am Purchase | 2021-03-25 | 13G | LAVA Therapeutics N.V. LVTX | SANOFI | 1,919,455 7.000% | 1,919,455 (New Position) | Filing History |
| 2021-03-31 08:27 am Purchase | 2021-03-26 | 13D | LAVA Therapeutics N.V. LVTX | Cooperatieve Gilde Healthcare IV U.A. | 5,421,170 21.380% | 5,421,170 (New Position) | Filing History |